Survival in Hodgkin's disease patients - Report of 25 years of experience at the Milan Cancer Institute

Gianni Bonadonna, Simonetta Viviani, Valeria Bonfante, Alessandro M. Gianni, Pinuccia Valagussa

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The aim of this study was to assess the long-term therapeutic outcome and risk of treatment-related complications in Hodgkin's disease. From May 1973 to September 1990, four randomised studies have been activated at the Milan Cancer Institute using nitrogen mustard, vincristine, procarbazine and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimens, with or without irradiation, involving a total of 811 patients with intermediate and advanced Hodgkin's disease. Overall, ABVD contributed to significantly reduce the relative risk of lymphoma progression and death compared with the MOPP regimen. With a prolonged follow-up, a total of 106 patients (75 of whom were in continuous complete remission after first-line chemotherapy) developed a variety of cancers, resulting in a total risk of 22.2%. Our 25 years of experience re-emphasises that ABVD can cure a high fraction of patients with Hodgkin's disease. However, patients in continuous complete remission, are at a high risk of developing second cancers, especially when the treatment strategy includes extensive irradiation. The main focus of future trials should be on reducing treatment sequelae to improve the quality of life of long-term survivors.

Original languageEnglish
Pages (from-to)998-1006
Number of pages9
JournalEuropean Journal of Cancer
Volume41
Issue number7
DOIs
Publication statusPublished - May 2005

Fingerprint

Hodgkin Disease
Dacarbazine
Vinblastine
Bleomycin
Doxorubicin
Survival
Neoplasms
Procarbazine
Mechlorethamine
Second Primary Neoplasms
Vincristine
Prednisone
Survivors
Lymphoma
Therapeutics
Quality of Life
Drug Therapy

Keywords

  • ABVD
  • Causes of death
  • Hodgkin's disease
  • MOPP
  • Second cancers

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Survival in Hodgkin's disease patients - Report of 25 years of experience at the Milan Cancer Institute. / Bonadonna, Gianni; Viviani, Simonetta; Bonfante, Valeria; Gianni, Alessandro M.; Valagussa, Pinuccia.

In: European Journal of Cancer, Vol. 41, No. 7, 05.2005, p. 998-1006.

Research output: Contribution to journalArticle

Bonadonna, Gianni ; Viviani, Simonetta ; Bonfante, Valeria ; Gianni, Alessandro M. ; Valagussa, Pinuccia. / Survival in Hodgkin's disease patients - Report of 25 years of experience at the Milan Cancer Institute. In: European Journal of Cancer. 2005 ; Vol. 41, No. 7. pp. 998-1006.
@article{db7bf6a18a394ddaaebb2c66343e0fc1,
title = "Survival in Hodgkin's disease patients - Report of 25 years of experience at the Milan Cancer Institute",
abstract = "The aim of this study was to assess the long-term therapeutic outcome and risk of treatment-related complications in Hodgkin's disease. From May 1973 to September 1990, four randomised studies have been activated at the Milan Cancer Institute using nitrogen mustard, vincristine, procarbazine and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimens, with or without irradiation, involving a total of 811 patients with intermediate and advanced Hodgkin's disease. Overall, ABVD contributed to significantly reduce the relative risk of lymphoma progression and death compared with the MOPP regimen. With a prolonged follow-up, a total of 106 patients (75 of whom were in continuous complete remission after first-line chemotherapy) developed a variety of cancers, resulting in a total risk of 22.2{\%}. Our 25 years of experience re-emphasises that ABVD can cure a high fraction of patients with Hodgkin's disease. However, patients in continuous complete remission, are at a high risk of developing second cancers, especially when the treatment strategy includes extensive irradiation. The main focus of future trials should be on reducing treatment sequelae to improve the quality of life of long-term survivors.",
keywords = "ABVD, Causes of death, Hodgkin's disease, MOPP, Second cancers",
author = "Gianni Bonadonna and Simonetta Viviani and Valeria Bonfante and Gianni, {Alessandro M.} and Pinuccia Valagussa",
year = "2005",
month = "5",
doi = "10.1016/j.ejca.2005.01.006",
language = "English",
volume = "41",
pages = "998--1006",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Survival in Hodgkin's disease patients - Report of 25 years of experience at the Milan Cancer Institute

AU - Bonadonna, Gianni

AU - Viviani, Simonetta

AU - Bonfante, Valeria

AU - Gianni, Alessandro M.

AU - Valagussa, Pinuccia

PY - 2005/5

Y1 - 2005/5

N2 - The aim of this study was to assess the long-term therapeutic outcome and risk of treatment-related complications in Hodgkin's disease. From May 1973 to September 1990, four randomised studies have been activated at the Milan Cancer Institute using nitrogen mustard, vincristine, procarbazine and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimens, with or without irradiation, involving a total of 811 patients with intermediate and advanced Hodgkin's disease. Overall, ABVD contributed to significantly reduce the relative risk of lymphoma progression and death compared with the MOPP regimen. With a prolonged follow-up, a total of 106 patients (75 of whom were in continuous complete remission after first-line chemotherapy) developed a variety of cancers, resulting in a total risk of 22.2%. Our 25 years of experience re-emphasises that ABVD can cure a high fraction of patients with Hodgkin's disease. However, patients in continuous complete remission, are at a high risk of developing second cancers, especially when the treatment strategy includes extensive irradiation. The main focus of future trials should be on reducing treatment sequelae to improve the quality of life of long-term survivors.

AB - The aim of this study was to assess the long-term therapeutic outcome and risk of treatment-related complications in Hodgkin's disease. From May 1973 to September 1990, four randomised studies have been activated at the Milan Cancer Institute using nitrogen mustard, vincristine, procarbazine and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimens, with or without irradiation, involving a total of 811 patients with intermediate and advanced Hodgkin's disease. Overall, ABVD contributed to significantly reduce the relative risk of lymphoma progression and death compared with the MOPP regimen. With a prolonged follow-up, a total of 106 patients (75 of whom were in continuous complete remission after first-line chemotherapy) developed a variety of cancers, resulting in a total risk of 22.2%. Our 25 years of experience re-emphasises that ABVD can cure a high fraction of patients with Hodgkin's disease. However, patients in continuous complete remission, are at a high risk of developing second cancers, especially when the treatment strategy includes extensive irradiation. The main focus of future trials should be on reducing treatment sequelae to improve the quality of life of long-term survivors.

KW - ABVD

KW - Causes of death

KW - Hodgkin's disease

KW - MOPP

KW - Second cancers

UR - http://www.scopus.com/inward/record.url?scp=18044394016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044394016&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.01.006

DO - 10.1016/j.ejca.2005.01.006

M3 - Article

C2 - 15862748

AN - SCOPUS:18044394016

VL - 41

SP - 998

EP - 1006

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -